MedCap AB (Sweden) Performance
| MCAP Stock | SEK 558.00 7.00 1.27% |
MedCap AB has a performance score of 5 on a scale of 0 to 100. The company secures a Beta (Market Risk) of 0.37, which conveys possible diversification benefits within a given portfolio. As returns on the market increase, MedCap AB's returns are expected to increase less than the market. However, during the bear market, the loss of holding MedCap AB is expected to be smaller as well. MedCap AB right now secures a risk of 2.5%. Please verify MedCap AB coefficient of variation, jensen alpha, and the relationship between the downside deviation and standard deviation , to decide if MedCap AB will be following its current price movements.
Risk-Adjusted Performance
5 of 100
Weak | Strong |
Modest
Compared to the overall equity markets, risk-adjusted returns on investments in MedCap AB are ranked lower than 5 (%) of all global equities and portfolios over the last 90 days. In spite of comparatively uncertain basic indicators, MedCap AB may actually be approaching a critical reversion point that can send shares even higher in January 2025. ...more
| Begin Period Cash Flow | 146.5 M | |
| Total Cashflows From Investing Activities | -64.8 M |
MedCap |
MedCap AB Relative Risk vs. Return Landscape
If you would invest 50,400 in MedCap AB on September 3, 2024 and sell it today you would earn a total of 5,400 from holding MedCap AB or generate 10.71% return on investment over 90 days. MedCap AB is generating 0.1872% of daily returns and assumes 2.4954% volatility on return distribution over the 90 days horizon. Simply put, 22% of stocks are less volatile than MedCap, and 97% of all equity instruments are likely to generate higher returns than the company over the next 90 trading days. Expected Return |
| Risk |
MedCap AB Market Risk Analysis
Today, many novice investors tend to focus exclusively on investment returns with little concern for MedCap AB's investment risk. Standard deviation is the most common way to measure market volatility of stocks, such as MedCap AB, and traders can use it to determine the average amount a MedCap AB's price has deviated from the expected return over a period of time. It is calculated by determining the expected price for the established period and then subtracting this figure from each price point. The differences are then squared, summed, and averaged to produce the variance.
Sharpe Ratio = 0.075
| Best Portfolio | Best Equity | |||
| Good Returns | ||||
| Average Returns | ||||
| Small Returns | MCAP | |||
| Cash | Small Risk | Average Risk | High Risk | Huge Risk |
| Negative Returns |
Estimated Market Risk
| 2.5 actual daily | 22 78% of assets are more volatile |
Expected Return
| 0.19 actual daily | 3 97% of assets have higher returns |
Risk-Adjusted Return
| 0.08 actual daily | 5 95% of assets perform better |
Based on monthly moving average MedCap AB is performing at about 5% of its full potential. If added to a well diversified portfolio the total return can be enhanced and market risk can be reduced. You can increase risk-adjusted return of MedCap AB by adding it to a well-diversified portfolio.
MedCap AB Fundamentals Growth
MedCap Stock prices reflect investors' perceptions of the future prospects and financial health of MedCap AB, and MedCap AB fundamentals are critical determinants of its market performance. Overall, investors pay close attention to revenue and earnings growth, profit margins, and debt levels. These fundamentals can have a significant impact on MedCap Stock performance.
| Return On Equity | 0.15 | |||
| Return On Asset | 0.0822 | |||
| Profit Margin | 0.10 % | |||
| Operating Margin | 0.15 % | |||
| Current Valuation | 3.15 B | |||
| Shares Outstanding | 14.81 M | |||
| Price To Earning | 197.02 X | |||
| Price To Book | 3.83 X | |||
| Price To Sales | 2.95 X | |||
| Revenue | 916.3 M | |||
| EBITDA | 200.3 M | |||
| Cash And Equivalents | 139.7 M | |||
| Cash Per Share | 1.17 X | |||
| Total Debt | 165.4 M | |||
| Debt To Equity | 102.00 % | |||
| Book Value Per Share | 57.83 X | |||
| Cash Flow From Operations | 116.3 M | |||
| Earnings Per Share | 7.98 X | |||
| Total Asset | 1.17 B | |||
| Current Asset | 392 M | |||
| Current Liabilities | 251 M | |||
About MedCap AB Performance
Assessing MedCap AB's fundamental ratios provides investors with valuable insights into MedCap AB's financial health and overall profitability. This information is crucial for making informed investment decisions. A high ROA would indicate that the MedCap AB is effectively leveraging its assets and equity to generate significant profits, making it an appealing investment. Conversely, low Return on Assets could signal underlying management issues in assets and equity, indicating a necessity for operational refinements. Please also refer to our technical analysis and fundamental analysis pages.
MedCap AB is a private equity firm specializing in investments in secondary direct, later stage, industry consolidation, growth capital, middle market, mature, turnarounds, buyout. MedCap AB was founded in 2001 and is based in Stockholm, Sweden. MedCap AB operates under Medical Equipment classification in Sweden and is traded on Stockholm Stock Exchange.Things to note about MedCap AB performance evaluation
Checking the ongoing alerts about MedCap AB for important developments is a great way to find new opportunities for your next move. Stock alerts and notifications screener for MedCap AB help investors to be notified of important events, changes in technical or fundamental conditions, and significant headlines that can affect investment decisions.| MedCap AB has high financial leverage indicating that it may have difficulties to generate enough cash to satisfy its financial obligations | |
| About 30.0% of the company outstanding shares are owned by corporate insiders |
- Analyzing MedCap AB's financial statements, including its income statement, balance sheet, and cash flow statement, helps in understanding its overall financial health and growth potential.
- Getting a closer look at valuation ratios like price-to-earnings (P/E) ratio, price-to-sales (P/S) ratio, and price-to-book (P/B) ratio help in understanding whether MedCap AB's stock is overvalued or undervalued compared to its peers.
- Examining MedCap AB's industry or sector and how it is performing can give you an idea of its growth potential and how it is positioned relative to its competitors.
- Evaluating MedCap AB's management team can have a significant impact on its success or failure. Reviewing the track record and experience of MedCap AB's management team can help you assess the Company's leadership.
- Pay attention to analyst opinions and ratings of MedCap AB's stock. These opinions can provide insight into MedCap AB's potential for growth and whether the stock is currently undervalued or overvalued.
Additional Tools for MedCap Stock Analysis
When running MedCap AB's price analysis, check to measure MedCap AB's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy MedCap AB is operating at the current time. Most of MedCap AB's value examination focuses on studying past and present price action to predict the probability of MedCap AB's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move MedCap AB's price. Additionally, you may evaluate how the addition of MedCap AB to your portfolios can decrease your overall portfolio volatility.